(PharmaNewsWire.Com, May 05, 2017 ) According to Publisher, the Global Enzyme Inhibitors Market is expected to grow at a CAGR of 4.3% during the forecast period 2016-2022. There has been an exponential rise in the occurrence of various diseases. Enzyme inhibitors are used as diagnostic agents to detect various diseases thus fueling the growth of Enzyme Inhibitor market. Moreover, usage of these inhibitors in the manufacturing of pesticides and herbicides favours the market growth. However, the existence of strict regulations increases the cost as well as launch period of new drugs, thereby hampering the growth of the global market.
Developing nations of North America and Europe has high growth because of improved diagnosis rate for the diseases, accessibility of medical facility and presence of established infrastructure. Asia Pacific market is expected to flourish due to the existence of large patient pool, enhancing healthcare infrastructure in developing nations such as India, China, and South Korea. Some of the key players in the market include Amgen, AstraZeneca, Bayer AG, Eli Lilly, Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer, Ranbaxy Laboratories Ltd, Roche and Takeda Pharma. Type of Enzyme Inhibitors Covered: -Reversible -Irreversible End Users Covered: -Agrochemical -Pharmaceutical -Biotechnology -Food & Beverage -Other End Users Disease Indications Covered: -Arthritis -Cardiovascular Disease -Chronic Obstructive Pulmonary Disorders -Gastrointestinal Disorders -Inflammatory Diseases -Other Diseases Applications Covered: -Pesticide Synthesis -Drug Development -Diagnostic Agent -Other Applications
Regions Covered: -North America -US -Canada -Mexico -Europe -Germany -France -Italy -UK -Spain -Rest of Europe -Asia Pacific -Japan -China -India -Australia -New Zealand -Rest of Asia Pacific -Rest of the World -Middle East -Brazil -Argentina -South Africa -Egypt
Company Profiling 11.1 Amgen 11.2 AstraZeneca 11.3 Bayer AG 11.4 Eli Lilly 11.5 Johnson & Johnson 11.6 Merck KGaA 11.7 Novartis AG 11.8 Pfizer 11.9 Ranbaxy Laboratories Ltd 11.10 Roche 11.11 Takeda Pharma
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
